Skip to content
Research Article Open access CC BY 4.0

Factors Affecting the Safety Profile of Intravenous Levetiracetam Used for Controlling Seizures in Children: A Literature Review

Samah Alyamani Abdalkarim Alakhdar

Asian Journal of Pediatric Research · pp. 1–7 · Published 20 Feb 2024

10.9734/ajpr/2024/v14i3327

Abstract

The administration of intravenous levetiracetam (IV-LEV) serves as a significant therapeutic approach for managing seizures in pediatric patients. The major factors that are involved in the equation determinants contain pharmacokinetic parameters, such as dosage regimen, drug interactions, and patient-specific factors including age, weight, and underlying comorbidities. Furthermore, attention is given to potential adverse effects, including hypersensitivity reactions, renal impairment, and central nervous system manifestations. Clinical trials, observational studies, and pharmacovigilance data contribute to a comprehensive evaluation of the drug’s safety, shedding light on optimal dosing strategies and risk mitigation techniques. Understanding these intricate factors is paramount for healthcare providers to ensure efficacious seizure control while minimizing potential harms associated with IV-LEV administration in children. This abstract examines the multifaceted factors that influence the safety profile of IV-LEV in this vulnerable pediatric population. This literature review explores the various factors influencing the safety profile of intravenous levetiracetam (IV-LEV) in its application for seizure management in pediatric patients. Based upon a comprehensive analysis of peer-reviewed articles, clinical trials, and observational studies, the review synthesizes findings related to pharmacokinetic variables, dosage considerations, and potential drug interactions. Additionally, patient-specific determinants, encompassing age-related variations, weight-based dosing implications, and the impact of comorbid conditions, are critically evaluated.

Levetiracetam pediatric population seizures in children intravenous administration of levetiracetam

References (24)

  1. 1 Clinical Pharmacokinetics of Levetiracetam [DOI]
  2. 2 Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures [DOI]
  3. 3 Levetiracetam in the treatment of epilepsy [DOI]
  4. 4 Behavioral side-effects of levetiracetam in children with epilepsy: A systematic review [DOI]
  5. 5 A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials [DOI]
  6. 6 Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): An open-label, parallel group trial [DOI]
  7. 7 The adverse effects profile of levetiracetam in epilepsy: a more detailed look [DOI]
  8. 8 Safety of Levetiracetam in Paediatrics: A Systematic Review [DOI]
  9. 9 Safety of lamotrigine in paediatrics: a systematic review [DOI]
  10. 10 Levetiracetam Monotherapy in Children with Epilepsy: A Systematic Review [DOI]
  11. 11 Rapid administration of undiluted intravenous levetiracetam [DOI]
  12. 12 IV Levetiracetam versus IV Phenytoin in childhood seizures: A randomized controlled trial [DOI]
  13. 13 Levetiracetam Induced Behavioral Abnormalities in a Patient with Seizure Disorder: A Diagnostic Challenge [DOI]
  14. 14 The safety of rapid infusion levetiracetam: A systematic review [DOI]
  15. 15 Methotrexate Elimination When Coadministered With Levetiracetam [DOI]
  16. 16 Efficacy and safety profile of intravenous levetiracetam versus phenytoin in convulsive status epilepticus and acute repetitive seizures in children [DOI]
  17. 17 Efficacy and Safety of IV Levetiracetam in Children With Acute Repetitive Seizures [DOI]
  18. 18 Optimization of levetiracetam dosing regimen in critically ill patients with augmented renal clearance: a Monte Carlo simulation study [DOI]
  19. 19 Pharmacokinetic and Pharmacodynamic Evaluation of Intravenous Levetiracetam in Children With Epilepsy [DOI]
  20. 20 Acute Kidney Injury Caused by Levetiracetam in a Patient With Status Epilepticus [DOI]
  21. 21 Pharmacokinetics and Proposed Dosing of Levetiracetam in Children With Obesity [DOI]
  22. 22 Effect of Levetiracetam on Time to High‐Dose Methotrexate Clearance in Patients With Hematologic Malignancies [DOI]
  23. 23 Efficacy and safety of levetiracetam in children with epilepsy: protocol for an umbrella review of systematic reviews and meta-analyses of randomised controlled trials [DOI]
  24. 24 The Efficacy and Safety Profile of Generic Intravenous Levetiracetam in a Real-World Setting [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

29

Page views

0

PDF downloads

4

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.